Novartis licensed a preclinical amyloid‑targeting brain‑shuttle program from SciNeuro for $165 million upfront with as much as $1.5 billion in additional milestones. The collaboration aims to advance a peptide‑ or antibody‑based shuttle to transport therapeutics across the blood‑brain barrier for Alzheimer’s and other CNS indications. The deal highlights pharma’s continued investment in BBB delivery technologies to improve CNS efficacy. Novartis will co‑develop early assets and has options to take programs forward, leveraging SciNeuro’s shuttle technology to augment its broader neuroscience portfolio and accelerate candidate selection for clinical development.